Four Lp(a)-lowering drugs in trials reduce levels by up to 94%

Recent trials have shown that four drugs designed to lower lipoprotein(a) levels can achieve reductions of up to 94%. This significant decrease could have major implications for cardiovascular health, as elevated Lp(a) is a known risk factor for heart disease. The results of these trials may pave the way for new treatment options in managing heart disease risk.